Psilocybin for the Treatment of Cluster Headache
Status: | Recruiting |
---|---|
Conditions: | Migraine Headaches |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 21 - 65 |
Updated: | 12/22/2018 |
Start Date: | November 2016 |
End Date: | November 2021 |
Contact: | Emmanuelle Schindler, MD, PhD |
Email: | emmanuelle.schindler@yale.edu |
Phone: | 203-932-5711 |
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen
in cluster headache. Subjects will be randomized to receive oral placebo, low dose
psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days.
Subjects will maintain a headache diary prior to, during, and after the pulse regimen in
order to document headache frequency and intensity before, during, and after the pulse
regimen.
in cluster headache. Subjects will be randomized to receive oral placebo, low dose
psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days.
Subjects will maintain a headache diary prior to, during, and after the pulse regimen in
order to document headache frequency and intensity before, during, and after the pulse
regimen.
Inclusion Criteria:
- Chronic cluster headache with at least one attack daily
- Episodic cluster headache with periods that are predictable and have a duration of
approximately 2 months
- Attacks are managed by means involving no more than twice weekly triptan use (e.g.,
high-flow oxygen, heat/cold pack)
Exclusion Criteria:
- Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)
- Axis I psychotic disorder in first degree relative
- Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or
serious central nervous system pathology
- Pregnant, breastfeeding, lack of adequate birth control
- History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related
compounds
- Drug or alcohol abuse within the past 3 months (excluding tobacco)
- Urine toxicology positive to drugs of abuse
- Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine)
within five half-lives of test days
- Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks
- Use of antidepressant medications (i.e. amitriptyline, isocarboxazid, fluoxetine,
citalopram) in the past 6 weeks
- Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the
past 2 weeks
We found this trial at
1
site
950 Campbell Ave
West Haven, Connecticut 06516
West Haven, Connecticut 06516
(203) 932-5711
Principal Investigator: Deepak Cyril D'Souza, MD
Phone: 203-932-5711
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
Click here to add this to my saved trials